news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Recently, the pharmaceutical sector, which has experienced a long period of adjustment, has shown signs of recovery. According to statistics, many pharmaceutical ETFs and active equity products have risen by more than 5% since July. In the view of many institutions, after three years of adjustment, the current pharmaceutical sector has entered the value investment range, coupled with the introduction of a number of favorable policies, and related investment opportunities are worthy of attention.

Choice data shows that many pharmaceutical-related funds have risen against the trend since July. As of August 8, Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 ETF, Fuguo CSI Shanghai-Hong Kong-Shenzhen Innovative Drug Industry ETF, Guotai CSI Shanghai-Hong Kong-Shenzhen Innovative Drug Industry ETF, Huatai-PineBridge CSI Shanghai-Hong Kong-Shenzhen Innovative Drug Industry ETF, Southern CSI Innovative Drug Industry ETF and many other pharmaceutical ETFs have risen by more than 5% since July. In terms of active equity products, as of August 8, the net value of many products such as SWM Pharmaceutical Pioneer Stock A, Yongying Pharmaceutical Health A, Tianhong Pharmaceutical Innovation A, and Yuanxin Yongfeng Pharmaceutical Health have all increased by more than 5% since July. (Shanghai Securities News)